Supreme Cannabis Company Inc.

Most Recent

  • uploads///AdobeStock_

    Valuation for Cannabis Stocks in October

    The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

    By Margaret Patrick
  • uploads///herb _
    Company & Industry Overviews

    Canopy Growth to Get Extract Supply from MediPharm Labs

    On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.

    By Adam Jones
  • uploads///Vaping

    Vaping Risks: Health Canada’s Warning, US Reports More Cases

    Health Canada issued a statement warning people about vaping risks. There have been more illnesses, possibly caused by vaping, in several US states.

    By Sirisha Bhogaraju
  • uploads///supreme cannabis outlook

    What to Expect from Supreme Cannabis in 2020

    Supreme Cannabis’s third-quarter revenue was 9.7 million Canadian dollars—lower than 9.9 million Canadian dollars in the third quarter of 2019.

    By Sushree Mohanty
  • uploads///Fire

    Supreme Cannabis: Lower Target Price after Q1 Earnings

    Following Supreme Cannabis’s weak first-quarter performance, PI Financial and Canaccord Genuity lowered their target prices.

    By Rajiv Nanjapla
  • uploads///Cannabis Roundup on FIRE ACB CGC and TLRY

    Cannabis Roundup on FIRE, ACB, CGC, and TLRY

    Cannabis stocks mostly traded in positive territory today. Supreme Cannabis (FIRE) and Aurora Cannabis (ACB) rose about 9.5% and 5.5%, respectively.

    By Adam Jones
  • uploads///Supreme Cannabis Analysts NTM Recommendation and Target
    Basic Materials

    Supreme Cannabis: Analysts’ Target Price in February

    Among cannabis stocks (MJ), Supreme Cannabis (SPRWF) has provided an impressive return of 47% YTD (year-to-date).

    By Adam Jones
  • uploads///herb _
    Company & Industry Overviews

    GW Pharmaceuticals Has Already Soared 23% in January

    GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.

    By Daniel Collins
  • uploads///Aphria Analysts NTM Recommendation and Target

    March Analyst Ratings and Price Targets for Aphria

    Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date).

    By Adam Jones
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.